Circulating tumor cell isolation and diagnostics: toward routine clinical use.
Standard
Circulating tumor cell isolation and diagnostics: toward routine clinical use. / van de Stolpe, Anja; Pantel, Klaus; Sleijfer, Stefan; Terstappen, Leon W; Toonder, den; Jaap, M J.
In: CANCER RES, Vol. 71, No. 18, 18, 2011, p. 5955-5960.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Circulating tumor cell isolation and diagnostics: toward routine clinical use.
AU - van de Stolpe, Anja
AU - Pantel, Klaus
AU - Sleijfer, Stefan
AU - Terstappen, Leon W
AU - Toonder, den
AU - Jaap, M J
PY - 2011
Y1 - 2011
N2 - From February 7-11, 2011, the multidisciplinary Lorentz Workshop Circulating Tumor Cell (CTC) Isolation and Diagnostics: Toward Routine Clinical Use was held in Leiden (The Netherlands) to discuss progress and define challenges and potential solutions for development of clinically useful circulating tumor cell (CTC) diagnostics. CTCs, captured as "liquid biopsy" from blood, for counting and characterization using pathology and molecular assays, are expected to replace metastatic tissue biopsies to be used to predict drug response and resistance and to monitor therapy response and cancer recurrence. CTCs are highly heterogeneous; therefore, cancer type-specific isolation technologies, as well as complex clinical interpretation software, are required.
AB - From February 7-11, 2011, the multidisciplinary Lorentz Workshop Circulating Tumor Cell (CTC) Isolation and Diagnostics: Toward Routine Clinical Use was held in Leiden (The Netherlands) to discuss progress and define challenges and potential solutions for development of clinically useful circulating tumor cell (CTC) diagnostics. CTCs, captured as "liquid biopsy" from blood, for counting and characterization using pathology and molecular assays, are expected to replace metastatic tissue biopsies to be used to predict drug response and resistance and to monitor therapy response and cancer recurrence. CTCs are highly heterogeneous; therefore, cancer type-specific isolation technologies, as well as complex clinical interpretation software, are required.
KW - Humans
KW - Neoplastic Cells, Circulating/pathology
KW - Neoplasms/blood/diagnosis/pathology
KW - Humans
KW - Neoplastic Cells, Circulating/pathology
KW - Neoplasms/blood/diagnosis/pathology
M3 - SCORING: Journal article
VL - 71
SP - 5955
EP - 5960
JO - CANCER RES
JF - CANCER RES
SN - 0008-5472
IS - 18
M1 - 18
ER -